PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 6, 2008, Pages 2518-2525

  Yang, Wanhua ^a   Chen, Peter W ^a   Li, Haochuan ^a   Alizadeh, Hassan ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; MEMBRANE PROTEIN; PD 1 ANTIBODY; PD L1 ANTIBODY; TRANSMEMBRANE GLYCOPROTEIN PD L1; TRANSMEMBRANE PROTEIN PD 1; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD274 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN; RECOMBINANT GAMMA INTERFERON; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CULTURE; CELL FUNCTION; CELL TYPE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA CELL LINE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR LOCALIZATION; UVEA MELANOMA; COCULTURE; DRUG EFFECT; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; UVEA TUMOR;

ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM METASTASIS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; UVEAL NEOPLASMS;

EID: 47249089536     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1606     Document Type: Article

References (55)

1. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239-251. (Pubitemid 18066234)
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-961.
3. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46(1):151-166. (Pubitemid 44124237)
4. Albert DM. The ocular melanoma story. LIII: Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol. 1997;123(6):729-741. (Pubitemid 27250918)
5. Augsburger JJ, Mullen D, Kleineidam M. Planned combined I-125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthalmic Surg. 1993;24(2):76-81. (Pubitemid 23088546)
6. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219-2223. (Pubitemid 23280150)
7. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670-676. (Pubitemid 32417373)
8. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):962-965.
9. Sutmuller RP, Schurmans LR, van Duivenvoorde LM, et al. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J Immunol. 2000;165(12):7308-7315. (Pubitemid 32001211)
10. Valmori D, Dutoit V, Ayyoub M, et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 2003;28:3:15. (Pubitemid 38865224)
11. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-854. (Pubitemid 35231542)
12. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129. (Pubitemid 44547756)
13. Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24(31):5060-5069. (Pubitemid 46631410)
14. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-745. (Pubitemid 46348742)
15. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2(4):293-299. (Pubitemid 33706339)
16. Goslings WR, Blom DJ, de Waard-Siebinga I, et al. Membrane-bound regulators of complement activation in uveal melanomas: CD46, CD55, and CD59 in uveal melanomas. Invest Ophthalmol Vis Sci. 1996;37(9):1884-1891. (Pubitemid 26265040)
17. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
18. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268. (Pubitemid 33706004)
19. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365-1369.
20. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193(7):839-846. (Pubitemid 32524533)
21. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-824. (Pubitemid 47241890)
22. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265-268. (Pubitemid 32667515)
23. Blank C, Brown I, Marks R, et al. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003;171(9):4574-4581. (Pubitemid 37310573)
24. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29-53. (Pubitemid 34293419)
25. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765-772. (Pubitemid 26148299)
26. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64(3):1140-1145. (Pubitemid 38176921)
27. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. (Pubitemid 34887242)
28. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119(2):317-327. (Pubitemid 43911896)
29. Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 2005;115(2):184-191. (Pubitemid 40693089)
30. Bresalier RS, Hujanen ES, Raper SE, et al. An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res. 1987;47(5):1398-1406. (Pubitemid 17023214)
31. Reinmuth N, Liu W, Ahmad SA, et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003;63(9):2079-2087. (Pubitemid 36538610)
32. Sternberg LR, Byrd JC, Yunker CK, Dudas S, Hoon VK, Bresalier RS. Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. Gastroenterology. 1999;116(2):363-371. (Pubitemid 29055359)
33. Li H, Alizadeh H, Niederkorn JY. Differential expression of chemokines receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci. 2008;49(2):636-643.
34. He YG, McCulley J. Growing human corneal epithelium on collagen shield and subsequent transfer to denuded cornea in vitro. Curr Eye Res. 1991;10:851-863.
35. Ma D, Niederkorn JY. Transforming growth factor-beta downregulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86(2):263-269.
36. Saunders PA, Hendrycks VR, Lidinsky WA, Woods ML. PD-L2: PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur J Immunol. 2005;35(12):3561-3569. (Pubitemid 43025536)
37. Usui Y, Okunuki Y, Hattori T, et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res. 2008;86(1):52-59. (Pubitemid 350212878)
38. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9(10):963-969. (Pubitemid 20372121)
39. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32(8):2201-2211.
40. Chen PW, Mellon JK, Mayhew E, et al. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res. 2007;85(5):617-625. (Pubitemid 47633574)
41. Sohn JH, Bora PS, Jha P, et al. Complement, innate immunity and ocular disease. Chem Immunol Allergy. 2007;92:105-114. (Pubitemid 47096900)
42. Repp AC, Mayhew ES, Howard K, Alizadeh H, Niederkorn JY. Role of Fas ligand in uveal melanoma-induced liver damage. Graefes Arch Clin Exp Ophthalmol. 2001;239(10):752-758. (Pubitemid 33061881)
43. Choi IH, Zhu G, Sica GL, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003;171(9):4650-4654. (Pubitemid 37310581)
44. Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol. 2002;169(11):6546-6553. (Pubitemid 36903507)
45. Eppihimer MJ, Gunn J, Freeman GJ, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002;9(2):133-145. (Pubitemid 135684689)
46. Petroff MG, Chen L, Phillips TA, et al. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod. 2003;68(5):1496-1504. (Pubitemid 36519751)
47. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med. 2005;202(12):1623-1626. (Pubitemid 41815867)
48. Godfrey DI, Hammond KJ, Poulton LD, et al. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21(11):573-583.
49. Radosevich M, Jager M, Ono SJ. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Exp Mol Pathol. 2007;82(1):68-76. (Pubitemid 46038265)
50. Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Invest Ophthalmol Vis Sci. 2004;45(9):3185-3195. (Pubitemid 39121854)
51. Elsässer-Beile U, Przytulski B, Gierschner D, et al. Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Prostate. 2000;45(1):1-7.
52. Elsässer-Beile U, Rindsfüser M, Grussenmeyer T, Schultze-Seemann W, Wetterauer U. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. Br J Cancer. 2000;83(5):637-641. (Pubitemid 30636306)
53. Oliver G, Yannelli J, Solomon D. Tumor-infiltrating lymphocytes: cytologic, phenotypic and morphometric analysis. Acta Cytol. 1996;40(4):691-694. (Pubitemid 26250345)
54. Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest. 2001;51(4):254-261. (Pubitemid 32620125)
55. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73(4):470-478. (Pubitemid 28005307)